Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ARCHIVE
ARCHIVE
- Meiji Seika to Strengthen Its Overseas Business Structures: Vice President Ogawa
January 29, 2001
- PAJ President Uehara Stresses Importance of Self-medication
January 29, 2001
- National Burden Rate Can Be Reduced 10% Through Reform: Koseisho Study Team
January 29, 2001
- Council to Study Ways to Supply Drug Information to Public
January 29, 2001
- Jovi to Increase Its Member Stores to 3,000
January 29, 2001
- REGULATORY NEWS IN BRIEF
January 29, 2001
- JIRA Aims at Introducing Medical Devices Law
January 29, 2001
- Clinical Trial Support System Established in 5 Nat'l Univ.
January 29, 2001
- Olympus Aims at \100 Bil. Sales with Genomic Healthcare
January 29, 2001
- In vitro Fertilization Using Sperm, Ova from Third Parties to Be Approved
January 29, 2001
- Economy, Trade, Industry Ministry to Help Handicapped Persons Obtain Access to Internet
January 29, 2001
- Daiichi Forms Alliance with MedGene
January 22, 2001
- R&D Investment by 9 Major Companies Increases 3.5% in First 6 Months
January 22, 2001
- SCRIP Tokyo Office Moves
January 22, 2001
- Daiichi Pure Chemicals Starts Contract SNP Analysis Services
January 22, 2001
- Merger with Mitsui Pharm Strengthens Schering Group's Product Line
January 22, 2001
- 15 Researchers Win AstraZeneca Asthma Research Award
January 22, 2001
- Cancer to Be Next 'Franchise' Area Following CNS, GI Fields: Mr Shinoda of Eisai
January 22, 2001
- New Kosei-Rodosho Inaugurated on Jan. 6
January 22, 2001
- Kyushu Univ. Opens Master's Course to Train Specialized Medical Professionals
January 22, 2001
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…